Papers: 31 Jan 2014 - 7 Feb 2014
PET imaging of focal demyelination and remyelination in a rat model of multiple sclerosis: comparison of [(11)C]MeDAS, [ (11)C]CIC and [ (11)C]PIB.
Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice.
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.
Mycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis.
Differential IL-10 production by DCs determines the distinct adjuvant effects of LPS and PTX in EAE induction.
The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease.
Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India.
Progressive resistance therapy is not the best way to rehabilitate deficits due to multiple sclerosis: Commentary.
Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning.
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.
A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: Changes in health-related quality of life and the value of different factors in predicting health-related quality of life.
Effect of vitamin D status on pharmacological treatment efficiency: Impact on cost-effective management in medicine.
Progressive resistance therapy is not the best way to rehabilitate deficits due to multiple sclerosis: No.
Progressive resistance therapy is not the best way to rehabilitate deficits due to multiple sclerosis: Yes.
Inter-hemispheric functional connectivity changes with corpus callosum morphology in multiple sclerosis.
Erratum to: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.
Thiopalmitoylation of Altered Peptide Ligands Enhances Their Protective Effects in an Animal Model of Multiple Sclerosis.
Are Hsp70 protein expression and genetic polymorphism implicated in multiple sclerosis inflammation?
The protective effects of bioactive (RS)-glucoraphanin on the permeability of the mice blood-brain barrier following experimental autoimmune encephalomyelitis.
Relation between EDSS and monosymptomatic or polysymptomatic onset in clinical manifestations of multiple sclerosis in Babol, northern Iran.
The Transcription Factor IRF8 Activates Integrin-Mediated TGF-β Signaling and Promotes Neuroinflammation.
The flavonoid-enriched fraction AF4 suppresses neuroinflammation and promotes restorative gene expression in a mouse model of experimental autoimmune encephalomyelitis.
Effect of Estrogen on Th1, Th2 and Th17 Cytokine Production by Proteolipid Protein and PHA Activated Peripheral Blood Mononuclear Cells Isolated from Multiple Sclerosis Patients.
Pertussis toxin modulates microglia and T cell profile to protect experimental autoimmune encephalomyelitis.
The TIM-3 pathway ameliorates Theiler's murine encephalomyelitis virus-induced demyelinating disease.
Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.
Disruption of Myelin Leads to Ectopic Expression of KV1.1 Channels with Abnormal Conductivity of Optic Nerve Axons in a Cuprizone-Induced Model of Demyelination.
Living with the unexplained: Coping, distress, and depression among women with chronic fatigue syndrome (CFS) and/or fibromyalgia comparedto an autoimmune disorder.
Genetic inactivation of PERK signaling in mouse oligodendrocytes: Normal developmental myelination with increased susceptibility to inflammatory demyelination.
On the role of physiological fluctuations in quantitative gradient echo MRI: implications for GEPCI, QSM, and SWI.
[Use of vitamins for correction of the functional state of cytochrome P450 systems at experimental allergic encephalomyelitis].
Chemokine-mediated redirection of T cells constitutes a critical mechanism of glucocorticoid therapy in autoimmune CNS responses.
Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis.
Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial.
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.
Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review.
Transplantation of Fas-deficient or wild-type neural stem/progenitor cells (NPCs) is equally efficient in treating experimental autoimmune encephalomyelitis (EAE).